A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
NCT01097070
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV-1 Infection
Interventions
DRUG:
Bevirimat
Sponsor
Myrexis Inc.